The data showed that a single treatment with NX-1207 produced durable significant improvement. Statistical analysis of the controlled data showed that the results for NX-1207 reached statistical significance when the comparison was done to a baseline matched group of placebo controls. The study, a placebo controlled double blind trial was conducted at 24 US sites and involved 103 unselected patients.
Nymox has encountered serious interest and several term sheet offers from potential large pharmaceutical company marketing partners for NX-1207. The company is carefully considering its options for future marketing arrangements for NX-1207.
Brian Doyle, global sales manager for Nymox, said: “The study showed that many patients required no further treatment for two years after a single office visit administration that took 5-10 minutes.”